BRIEF-FDA approves expanded use of ENBREL to treat children with chronic moderate-to-severe plaque psoriasis

* Amgen Inc - FDA has approved SBLA for expanded use of ENBREL to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis